Inventor · disambiguated record
Huey-Ching Su
Also filed as: SU HUEY-CHING · SU HUEY-CHING L
15 granted patents·19 pending applications·110 citations·filing 2008–2021
92Inventor score
Top patents by PatentIndex Score
34 records- 0197US8415401B2Oral pharmaceutical dosage formsYUM SU IL·Filed 2008·Granted Apr 9, 2013·64 cites·19 claims
- 0293US9572885B2Compositions with a rheological modifier to reduce dissolution variabilityDURECT CORP·Filed 2014·Granted Feb 21, 2017·8 cites·26 claims
- 0390US9655861B2Oral pharmaceutical dosage formsDURECT CORP·Filed 2015·Granted May 23, 2017·6 cites·16 claims
- 0490US9555113B2Compositions with a rheological modifier to reduce dissolution variabilityDURECT CORP·Filed 2014·Granted Jan 31, 2017·5 cites·19 claims
- 0589US10682340B2Depot formulationsDURECT CORP·Filed 2017·Granted Jun 16, 2020·4 cites·19 claims
- 0689US9616055B2Oral pharmaceutical dosage formsDURECT CORP·Filed 2015·Granted Apr 11, 2017·7 cites·17 claims
- 0789US9592204B2Oral pharmaceutical dosage formsDURECT CORP·Filed 2013·Granted Mar 14, 2017·8 cites·17 claims
- 0888US9855333B2Compositions with a rheological modifier to reduce dissolution variabilityDURECT CORP·Filed 2017·Granted Jan 2, 2018·2 cites·25 claims
- 0984US9884056B2Oral pharmaceutical dosage formsDURECT CORP·Filed 2017·Granted Feb 6, 2018·3 cites·16 claims
- 1083US10328068B2Oral pharmaceutical dosage formsDURECT CORP·Filed 2017·Granted Jun 25, 2019·2 cites·20 claims
- 1180US10668011B2Depot formulationsDURECT CORP·Filed 2017·Granted Jun 2, 2020·1 cites·10 claims
- 1274US2021322517A1Biodegradable drug delivery compositionDURECT CORP·Filed 2021·Application pending·0 cites
- 1371US2019209654A1Biodegradable Drug Delivery CompositionDURECT CORP·Filed 2018·Application pending·0 cites
- 1471US2020101021A1Oral pharmaceutical dosage formsDURECT CORP·Filed 2019·Application pending·0 cites
- 1570US2018236078A1Compositions with a Rheological Modifier to Reduce Dissolution VariabilityDURECT CORP·Filed 2018·Application pending·0 cites
- 1669US2019231702A1Oral Pharmaceutical Dosage FormsDURECT CORP·Filed 2018·Application pending·0 cites
- 1768US10206883B2Oral pharamaceutical dosage formsDURECT CORP·Filed 2017·Granted Feb 19, 2019·0 cites·20 claims
- 1868US9907851B2Compositions with a rheological modifier to reduce dissolution variabilityDURECT CORP·Filed 2016·Granted Mar 6, 2018·0 cites·11 claims
- 1968US2010260844A1Oral pharmaceutical dosage formsSCICINSKI JAN J·Filed 2009·Application pending·0 cites
- 2066US2013259907A1Biodegradable Drug Delivery CompositionDURECT CORP·Filed 2013·Application pending·0 cites
- 2166US2020000791A1Oral pharmaceutical dosage formsDURECT CORP·Filed 2019·Application pending·0 cites
- 2265US10300142B2Compositions with a rheological modifier to reduce dissolution variabilityDURECT CORP·Filed 2017·Granted May 28, 2019·0 cites·20 claims
- 2365US2017189547A1Biodegradable Drug Delivery CompositionDURECT CORP·Filed 2016·Application pending·0 cites
- 2464US2017319501A1Oral Pharmaceutical Dosage FormsDURECT CORP·Filed 2017·Application pending·0 cites
- 2562US2012225033A1Biodegradable Drug Delivery CompositionVAN OSDOL WILLIAM W·Filed 2011·Application pending·0 cites
- 2661US2014193365A1Biodegradable Drug Delivery CompositionDURECT CORP·Filed 2013·Application pending·0 cites
- 2761US2009123518A1Biodegradable implants with controlled bulk densityYUM SU IL·Filed 2008·Application pending·0 cites
- 2861US2014011842A1Oral Pharmaceutical Dosage FormsDURECT CORP·Filed 2013·Application pending·0 cites
- 2959US2021169902A1Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesionsUNIV VIRGINIA COMMONWEALTH·Filed 2020·Application pending·0 cites
- 3058US2020383957A1Depot formulationsDURECT CORP·Filed 2020·Application pending·0 cites
- 3158US2020352852A1Depot formulationsDURECT CORP·Filed 2020·Application pending·0 cites
- 3255US2019374554A1Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesionsUNIV VIRGINIA COMMONWEALTH·Filed 2017·Application pending·0 cites
- 3353US2016038479A1Compositions with Thixotropy and Enhanced Dissolution Reproducibility and StabilityDURECT CORP·Filed 2014·Application pending·0 cites
- 3432US12274794B2Oral dosage form with drug composition, barrier layer and drug layerORIENT PHARMA CO LTD·Filed 2017·Granted Apr 15, 2025·0 cites·12 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →